Close×

Tetra Pak has pledged to increase its use of renewable electricity from 20 per cent to 100 per cent across all its worldwide operations by 2030.

The company has joined RE100, which is a global business initiative led by a non-profit organisation The Climate Group, in partnership with CDP.

Tetra Pak product management and commercial operations executive vice-president Charles Brand said the company was seeking to minimise its impact on the climate and environment, as well as enhancing the use of renewable resources.

"In 2015, emissions were down 15 per cent from the 2010 baseline, despite a 16 per cent increase in production," he said.

"We have set an ambitious target to ensure carbon emissions across our value chain are capped at 2010 levels through to 2020, and we are making excellent progress.

"In 2015, emissions were down 15 per cent from the 2010 baseline, despite a 16 per cent increase in production.

"Since setting our climate goal we've maximised our efforts to reduce energy consumption.

Committing to a renewable electricity target is a natural next step.

“By joining RE100 we will benefit from guidance and peer-to-peer learning on renewable electricity options in different markets."

RE100 was launched at Climate Week NYC in 2014, and 65 companies have joined the initiative since then.

Tetra Pak recently joined the Paris Pledge for Action at COP21.

Food & Drink Business

Australia’s first social enterprise bakery, The Bread & Butter Project, has graduated its latest group of bakers, with its largest ever cohort marking the program’s 100th graduate.

The University of Sydney and Peking University have launched a Joint Centre for Food Security and Sustainable Agricultural Development, which will support research into improving the sustainability and security of food systems in Australia and China.

Sydney-based biotech company, All G, has secured regulatory approval in China to sell recombinant (made from microbes, not cows) lactoferrin. CEO Jan Pacas says All G is the first company in the world to receive the approval, and recombinant human lactoferrin is “next in line”.